HK1038040A1 - Non-endogenous, constitutively activated human g protein-coupled receptors - Google Patents

Non-endogenous, constitutively activated human g protein-coupled receptors

Info

Publication number
HK1038040A1
HK1038040A1 HK01108940A HK01108940A HK1038040A1 HK 1038040 A1 HK1038040 A1 HK 1038040A1 HK 01108940 A HK01108940 A HK 01108940A HK 01108940 A HK01108940 A HK 01108940A HK 1038040 A1 HK1038040 A1 HK 1038040A1
Authority
HK
Hong Kong
Prior art keywords
endogenous
sub
sup
codon
gpcr
Prior art date
Application number
HK01108940A
Other languages
English (en)
Inventor
Dominic P Behan
Derek T Chalmers
Chen W Liaw
Original Assignee
Arena Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharm Inc filed Critical Arena Pharm Inc
Publication of HK1038040A1 publication Critical patent/HK1038040A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/16—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HK01108940A 1998-10-13 2001-12-20 Non-endogenous, constitutively activated human g protein-coupled receptors HK1038040A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/170,496 US6555339B1 (en) 1997-04-14 1998-10-13 Non-endogenous, constitutively activated human protein-coupled receptors
PCT/US1999/023938 WO2000022129A1 (fr) 1998-10-13 1999-10-12 Recepteurs couples a la proteine g humaine non endogenes et actives de façon constitutive

Publications (1)

Publication Number Publication Date
HK1038040A1 true HK1038040A1 (en) 2002-03-01

Family

ID=22620080

Family Applications (1)

Application Number Title Priority Date Filing Date
HK01108940A HK1038040A1 (en) 1998-10-13 2001-12-20 Non-endogenous, constitutively activated human g protein-coupled receptors

Country Status (15)

Country Link
US (2) US6555339B1 (fr)
EP (1) EP1121431B9 (fr)
JP (2) JP4685241B2 (fr)
KR (1) KR100598752B1 (fr)
CN (1) CN1329511C (fr)
AT (1) ATE318311T1 (fr)
AU (5) AU769987B2 (fr)
CA (1) CA2342314A1 (fr)
DE (3) DE69929993D1 (fr)
DK (1) DK1121431T5 (fr)
ES (1) ES2163384T3 (fr)
HK (1) HK1038040A1 (fr)
IL (2) IL141965A0 (fr)
NZ (1) NZ510331A (fr)
WO (2) WO2000022129A1 (fr)

Families Citing this family (168)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
US6555339B1 (en) * 1997-04-14 2003-04-29 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human protein-coupled receptors
USRE42190E1 (en) 1998-11-20 2011-03-01 Arena Pharmaceuticals, Inc. Method of identifying a compound for inhibiting or stimulating human G protein-coupled receptors
ATE366815T1 (de) * 1998-11-20 2007-08-15 Arena Pharm Inc Menschliche, an ein g-protein gekoppelter rezeptor rup3 ohne bekannten ligand
US20030017528A1 (en) 1998-11-20 2003-01-23 Ruoping Chen Human orphan G protein-coupled receptors
US7816492B2 (en) * 1998-11-20 2010-10-19 Arena Pharmaceuticals, Inc. Human G protein-coupled receptors
GB9903767D0 (en) * 1999-02-18 1999-04-14 Univ Glasgow Receptor assay
EP1235931A2 (fr) * 1999-07-30 2002-09-04 Millennium Pharmaceuticals, Inc. Compositions, kits, et methodes de prevision, de diagnostic, de prevention, et de traitement de maladies des os et d'autres maladies
JP4768946B2 (ja) * 1999-11-17 2011-09-07 アリーナ ファーマシューティカルズ， インコーポレイテッド ヒトｇタンパク質共役型受容体の内因性および非内因性型
AU5787901A (en) * 1999-12-10 2001-07-09 Astrazeneca Ab Compound
WO2001044295A2 (fr) * 1999-12-17 2001-06-21 Astrazeneca Ab Nouveau compose
GB0003902D0 (en) * 2000-02-18 2000-04-05 Glaxo Group Ltd Assay
GB0003898D0 (en) * 2000-02-18 2000-04-05 Glaxo Group Ltd Assay
EP1255779A2 (fr) * 2000-02-18 2002-11-13 Glaxo Group Limited Identification de modulateurs de l'activite gpr41 ou gpr42
AU2001241778A1 (en) * 2000-02-29 2001-09-12 Millennium Pharmaceuticals, Inc. Methods and compositions for the diagnosis and treatment of cardiovascular, hepatic, and bone disease
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
EP1149907A1 (fr) * 2000-04-26 2001-10-31 Aventis Pharma Deutschland GmbH Récepteur EDG8, sa préparation ainsi que son utilisation
KR100790329B1 (ko) * 2000-04-26 2008-01-02 사노피-아벤티스 도이칠란트 게엠베하 Ｅｄｇ8 수용체의 용도
EP1297127A2 (fr) * 2000-05-03 2003-04-02 AstraZeneca AB Modulateurs du gpr22 comme agents de controle de l'appetit
WO2001096567A1 (fr) * 2000-06-15 2001-12-20 Takeda Chemical Industries, Ltd. Nouvelle proteine receptrice couplee a la proteine g et adn de ce recepteur
WO2001098351A2 (fr) * 2000-06-16 2001-12-27 Incyte Genomics, Inc. Recepteurs couples a la proteine g
AU2001274562A1 (en) 2000-06-21 2002-01-02 Takeda Chemical Industries Ltd. Ligand to gpr8 and dna thereof
WO2002002767A1 (fr) * 2000-07-04 2002-01-10 Takeda Chemical Industries, Ltd. Proteine de recepteur couple a la proteine g et adn correspondant
WO2002013845A2 (fr) * 2000-08-18 2002-02-21 Novartis Ag Inflammation associee au recepteur couple a la proteine g
US7462457B2 (en) * 2000-08-30 2008-12-09 Johns Hopkins University School Of Medicine Identification of activated receptors and ion channels
WO2001027632A2 (fr) * 2000-10-02 2001-04-19 Biofocus Discovery Limited Procede de prediction de mutations
WO2002044368A1 (fr) * 2000-11-30 2002-06-06 Takeda Chemical Industries, Ltd. Nouvelles proteines du recepteur couple a la proteine g et leurs adn
GB0031527D0 (en) * 2000-12-22 2001-02-07 Smithkline Beecham Plc New use
US7241579B2 (en) 2000-12-22 2007-07-10 Smithkline Beecham Corporation Method of screening for GPR40 ligands
EP1412372A4 (fr) * 2001-02-26 2005-08-24 Arena Pharm Inc Versions endogenes et non-endogenes des recepteurs humains couples a la proteine-g
US6809104B2 (en) 2001-05-04 2004-10-26 Tularik Inc. Fused heterocyclic compounds
US6919176B2 (en) * 2001-05-07 2005-07-19 Amgen Inc. Polypeptides and nucleic acids associated with cancer
WO2002093161A1 (fr) * 2001-05-15 2002-11-21 Takeda Chemical Industries, Ltd. Methode de balayage
US20020177190A1 (en) * 2001-05-24 2002-11-28 Yanbin Liang Recombinant simian GPR3 receptor
CA2449553A1 (fr) * 2001-06-05 2002-12-19 Arena Pharmaceuticals, Inc. Versions non endogenes consecutivement activees de recepteur couple a une proteine g de vegetal: gcr1
JP2003018992A (ja) * 2001-06-28 2003-01-21 Inst Of Physical & Chemical Res Ｐａｅｌ受容体、Ｐａｅｌ受容体発現細胞および動物、ならびにパーキンソン病治療薬のスクリーニング法
AU2002325314B2 (en) * 2001-07-13 2008-07-10 N.V. Organon Allelic variants of GPR50
US20030109044A1 (en) * 2001-10-16 2003-06-12 Millennium Pharmaceuticals, Inc. Methods of using 279, a human G protein-coupled protein receptor
JP2005507673A (ja) * 2001-11-05 2005-03-24 ミレニアム・ファーマシューティカルズ・インコーポレイテッド １３９、２５８、１２６１、１４８６、２３９８、２４１４、７６６０、８５８７、１０１８３、１０５５０、１２６８０、１７９２１、３２２４８、６０４８９または９３８０４を用いる心血管疾患を治療するための方法および組成物
US6902902B2 (en) 2001-11-27 2005-06-07 Arena Pharmaceuticals, Inc. Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders
JP4360915B2 (ja) 2002-01-07 2009-11-11 ユーロスクリーン・ソシエテ・アノニム Ｇタンパク質共役受容体ｇｐｒ４３のリガンドおよびその使用
EP1336655A1 (fr) * 2002-01-12 2003-08-20 Aventis Pharma Deutschland GmbH Méthode pour l'identification des mutants ayant une actività constitutive
US20030175889A1 (en) * 2002-01-23 2003-09-18 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated versions of human G protein coupled receptor: FSHR
WO2003066077A2 (fr) * 2002-02-06 2003-08-14 Bayer Healthcare Ag Outil de diagnostic et therapeutique pour des maladies associees au recepteur de neuromedine u1 (nmu1)
AU2003211952A1 (en) 2002-02-14 2003-09-04 Takeda Chemical Industries, Ltd. Novel screening method
WO2003078602A2 (fr) * 2002-03-15 2003-09-25 Arena Pharmaceuticals, Inc. Methodes d'expression de recepteurs couples a la proteine g non endogene dans des cellules
AU2003241037A1 (en) * 2002-06-08 2003-12-22 Astrazeneca Ab Methods for the detection of polymorphisms in human gpr50
CN100473662C (zh) * 2002-08-01 2009-04-01 阿瑞那制药公司 治疗缺血性心脏病及充血性心衰竭的人类g蛋白偶联受体及其调节物
WO2004015427A2 (fr) * 2002-08-06 2004-02-19 Bayer Healthcare Ag Methodes diagnostiques et therapeutiques s'adressant a des maladies associees au recepteur 19 couple a la proteine g (gpr19)
WO2004015426A1 (fr) * 2002-08-06 2004-02-19 Bayer Healthcare Ag Agents diagnostiques et therapeutiques contre des maladies associees au recepteur 5 de la chemokine cxc humain (cxcr5)
WO2004017994A1 (fr) * 2002-08-22 2004-03-04 Kyowa Hakko Kogyo Co., Ltd. Medicaments preventifs et/ou therapeutiques contre l'asthme
WO2004038407A2 (fr) * 2002-10-24 2004-05-06 Bayer Healthcare Ag Diagnostics et medicaments pour maladies associees au recepteur 12 humain couple a la proteine g (gpr12)
US7056685B1 (en) 2002-11-05 2006-06-06 Amgen Inc. Receptor ligands and methods of modulating receptors
CA2505372A1 (fr) 2002-11-06 2004-05-27 Tularik Inc. Composes heterocycliques condenses
EP2385032A1 (fr) 2002-11-08 2011-11-09 Takeda Pharmaceutical Company Limited Régulateur de fonction de récepteur GPR40
US7189524B1 (en) 2002-11-25 2007-03-13 Amgen, Inc. Receptor ligands and methods of modulating receptors
AU2003297644A1 (en) * 2002-12-04 2004-06-23 Synaptic Pharmaceutical Corporation Uses of the snorf55 receptor
US20040157253A1 (en) * 2003-02-07 2004-08-12 Millennium Pharmaceuticals, Inc. Methods and compositions for use of inflammatory proteins in the diagnosis and treatment of metabolic disorders
US7094572B2 (en) * 2003-03-14 2006-08-22 Bristol-Myers Squibb Polynucleotide encoding a novel human G-protein coupled receptor variant of HM74, HGPRBMY74
WO2004083394A2 (fr) * 2003-03-18 2004-09-30 Arena Pharmaceuticals Inc. Recepteurs humains couples a la proteine g et modulateurs de ceux-ci destines au traitement de troubles inflammatoires
WO2004093912A1 (fr) * 2003-04-23 2004-11-04 Kyowa Hakko Kogyo Co. Ltd. Agent prophylactique et/ou therapeutique contre les maladies inflammatoires a neutrophiles
US20080009551A1 (en) * 2003-04-30 2008-01-10 Arena Pharmaceuticals, Inc. Methods and Compositions for Identifying Modulators of G Protein-Coupled Receptors
CA2525286C (fr) * 2003-05-20 2012-09-11 The University Court Of The University Of Glasgow Substances et methodes associees aux oligomeres des recepteurs couples a une proteine g
EP1666880B1 (fr) * 2003-09-11 2008-08-20 Takeda Pharmaceutical Company Limited Methode de criblage
AU2004279438A1 (en) * 2003-10-09 2005-04-21 Inverseon, Inc. Methods for treating diseases and conditions with inverse agonists
US20070276024A1 (en) * 2003-10-09 2007-11-29 Inverseon , Inc. Methods for Treating Diseases and Conditions with Inverse Agonists and for Screening for Agents Acting as Inverse Agonists
WO2005040829A2 (fr) * 2003-10-21 2005-05-06 Bayer Healthcare Ag Agents de diagnostic et de traitement des maladies associees au recepteur 17 couple aux proteines g (gpr17)
WO2005040211A2 (fr) * 2003-10-23 2005-05-06 Bayer Healthcare Ag Composes destines au diagnostic et au traitement de maladies associees au recepteur 1 couple aux proteines g (gpr1)
WO2005040828A2 (fr) * 2003-10-24 2005-05-06 Bayer Healthcare Ag Agents de diagnostic et de traitement des maladies associees au recepteur 49 couple aux proteines g (gpr49)
WO2005040825A2 (fr) * 2003-10-24 2005-05-06 Bayer Healthcare Ag Diagnostics et therapeutiques pour maladies liees au recepteur 20 couple a la proteine g (gpr20)
US7498298B2 (en) 2003-11-06 2009-03-03 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
PT1713501E (pt) * 2004-01-29 2008-04-30 Cellzome Ag Tratamento de doenças neurodegenerativas através da utilização de gpr49
CN1929833A (zh) 2004-02-20 2007-03-14 安万特药物公司 Hm74的氧杂十氢萘调节剂
WO2005101005A1 (fr) * 2004-04-15 2005-10-27 Bayer Healthcare Ag Diagnostics et methodes therapeutiques pour des maladies associees au recepteur 32 couple a la proteine g (grp32)
EP1741792B1 (fr) * 2004-04-27 2010-11-03 Takeda Pharmaceutical Company Limited Nouveau ligand de protéine de récepteur conjuguée à une protéine g et utilisation de celui-ci
CA2567520A1 (fr) 2004-06-01 2005-12-15 Genentech, Inc. Conjugues anticorps-maytansinoides
SI1791565T1 (sl) 2004-09-23 2016-08-31 Genentech, Inc. Cisteinsko konstruirana protitelesa in konjugati
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
US7528175B2 (en) * 2004-10-08 2009-05-05 Inverseon, Inc. Method of treating airway diseases with beta-adrenergic inverse agonists
GB0508988D0 (en) * 2005-05-03 2005-06-08 Novartis Ag Organic compounds
US8429755B2 (en) 2005-05-26 2013-04-23 Sandisk Technologies Inc. System and method for receiving digital content
US8673848B2 (en) 2012-01-27 2014-03-18 Novartis Ag Synthetic apelin mimetics for the treatment of heart failure
EP1934346A1 (fr) * 2005-10-14 2008-06-25 Arena Pharmaceuticals, Inc. Gpr22 et methodes associees
CA2627877A1 (fr) * 2005-11-10 2007-05-24 Arena Pharmaceuticals, Inc. Recepteur humain couple aux proteines g et ses modulateurs pour le traitement de l'obesite et de maladies associees
GB2456235B8 (en) 2007-03-22 2009-12-09 Heptares Therapeutics Ltd Stable beta-adrenergic receptor mutants
GB0724051D0 (en) 2007-12-08 2008-01-16 Medical Res Council Mutant proteins and methods for producing them
GB0724860D0 (en) 2007-12-20 2008-01-30 Heptares Therapeutics Ltd Screening
GB0802474D0 (en) 2008-02-11 2008-03-19 Heptares Therapeutics Ltd Mutant proteins and methods for selecting them
EP2146210A1 (fr) 2008-04-07 2010-01-20 Arena Pharmaceuticals, Inc. Procédés d'utilisation du récepteur couplé aux protéines A G pour identifier les secrétagogues de peptide YY (PYY) et composés utiles dans le traitement d'états modulés par PYY
WO2010091692A2 (fr) * 2009-04-30 2010-08-19 H. Lundbeck A/S Mutants actifs de manière constitutive et utilisations de ces derniers
GB0910725D0 (en) 2009-06-22 2009-08-05 Heptares Therapeutics Ltd Mutant proteins and methods for producing them
US8470980B2 (en) 2009-09-09 2013-06-25 Centrose, Llc Extracellular targeted drug conjugates
MA34277B1 (fr) 2010-04-15 2013-06-01 Spirogen Developments Sarl Pyrrolobenzodiazépines et conjugués de celles-ci
US9000130B2 (en) 2010-06-08 2015-04-07 Genentech, Inc. Cysteine engineered antibodies and conjugates
JP5804341B2 (ja) * 2010-08-06 2015-11-04 国立大学法人山口大学 エストロゲン関連疾患の判定方法
US20120121615A1 (en) 2010-11-17 2012-05-17 Flygare John A Alaninyl maytansinol antibody conjugates
CA2833212C (fr) 2011-05-12 2020-06-09 Genentech, Inc. Reaction multiple de surveillance du procede lc-ms/ms pour detecter les anticorps therapeutiques dans les echantillons d'animaux par des peptides de signature du cadre
AU2012322607B2 (en) 2011-10-14 2017-02-16 Genentech, Inc. Pyrrolobenzodiazepines and conjugates thereof
WO2013130093A1 (fr) 2012-03-02 2013-09-06 Genentech, Inc. Biomarqueurs pour un traitement à base de composés chimiothérapeutiques anti-tubuline
PL2906298T3 (pl) 2012-10-12 2019-04-30 Adc Therapeutics Sa Koniugaty pirolobenzodiazepina - przeciwciało
PL2906251T3 (pl) 2012-10-12 2018-02-28 Adc Therapeutics Sa Koniugaty pirolobenzodiazepina-przeciwciało anty-CD22
ES2680153T3 (es) 2012-10-12 2018-09-04 Adc Therapeutics Sa Conjugados de anticuerpos anti-PSMA-pirrolobenzodiazepinas
TR201815418T4 (tr) 2012-10-12 2018-11-21 Adc Therapeutics Sa Pirrolobenzodiazepin -anti-psma antikor konjugatları.
SI2906296T1 (en) 2012-10-12 2018-06-29 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
CN104837502B (zh) 2012-10-12 2018-08-10 麦迪穆有限责任公司 吡咯并苯并二氮杂卓及其结合物
WO2014057120A1 (fr) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Conjugués anticorps - pyrrolobenzodiazépine
US8921307B2 (en) 2012-11-20 2014-12-30 Novartis Ag Synthetic linear apelin mimetics for the treatment of heart failure
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
CN110627797A (zh) 2012-12-21 2019-12-31 麦迪穆有限责任公司 用于治疗增殖性和自身免疫疾病的非对称吡咯并苯并二氮杂卓二聚物
AU2013366493B2 (en) 2012-12-21 2017-08-24 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
KR102066319B1 (ko) 2013-03-13 2020-01-14 메디뮨 리미티드 피롤로벤조디아제핀 및 그의 컨쥬게이트
CA2901941C (fr) 2013-03-13 2020-04-07 Spirogen Sarl Pyrrolobenzodiazepines et leurs conjugues
BR112015021965B1 (pt) 2013-03-13 2022-05-03 Medimmune Limited Conjugados e compostos de pirrolobenzodiazepinas, composição farmacêutica, uso dos mesmos para o tratamento de uma doença proliferativa e método de síntese dos ditos compostos
MX2016001021A (es) 2013-07-25 2016-08-03 Novartis Ag Bioconjugados de polipeptidos de apelina sinteticos.
UY35670A (es) 2013-07-25 2015-02-27 Novartis Ag Polipéptidos cíclicos para el tratamiento de insuficiencia cardíaca
WO2015023355A1 (fr) 2013-08-12 2015-02-19 Genentech, Inc. Conjugués anticorps-médicament dimérique 1-(chlorométhyl)-2,3-dihydro-1 h-benzo [e]indole, et méthodes d'utilisation et de traitement
US9950078B2 (en) 2013-10-11 2018-04-24 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
EP3054986B1 (fr) 2013-10-11 2019-03-20 Medimmune Limited Conjugués anticorps-pyrrolobenzodiazépine
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
US10010624B2 (en) 2013-10-11 2018-07-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
KR20160092024A (ko) 2013-12-16 2016-08-03 제넨테크, 인크. 1-(클로로메틸)-2,3-디히드로-1H-벤조[e]인돌 이량체 항체-약물 접합체 화합물, 및 사용 및 치료 방법
KR20170042495A (ko) 2013-12-16 2017-04-19 제넨테크, 인크. 펩티드모방체 화합물 및 그의 항체-약물 접합체
MX371092B (es) 2013-12-16 2020-01-16 Genentech Inc Compuestos peptidomimeticos y conjugados de anticuerpo-farmaco de los mismos.
CA2945706C (fr) 2014-04-25 2023-10-24 Libramen Naturals Inc. Lignees cellulaires transformees pour exprimer le recepteur couple a la proteine g gpcr22 et utilisations associees
WO2016037644A1 (fr) 2014-09-10 2016-03-17 Medimmune Limited Pyrrolobenzodiazépines et leurs conjugués
US10149913B2 (en) 2014-09-12 2018-12-11 Genentech, Inc. Anthracycline disulfide intermediates, antibody-drug conjugates and methods
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
CN107108724A (zh) 2014-09-12 2017-08-29 豪夫迈·罗氏有限公司 半胱氨酸改造抗体和缀合物
AU2015317653A1 (en) 2014-09-17 2017-04-06 Genentech, Inc. Pyrrolobenzodiazepines and antibody disulfide conjugates thereof
WO2016083468A1 (fr) 2014-11-25 2016-06-02 Adc Therapeutics Sa Conjugués anticorps-pyrrolobenzodiazépine
CN107206101B (zh) 2014-12-03 2021-06-25 基因泰克公司 季铵化合物及其抗体-药物缀合物
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
MA45326A (fr) 2015-10-20 2018-08-29 Genentech Inc Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
WO2017140803A1 (fr) 2016-02-16 2017-08-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Modulateurs de résistance des tumeurs au système immunitaire pour le traitement du cancer
WO2017140793A1 (fr) 2016-02-16 2017-08-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Modulateurs de ccr9 pour le traitement de la résistance tumorale aux réponses immunitaires
EP4273551A3 (fr) 2016-03-25 2024-01-17 F. Hoffmann-La Roche AG Dosage multiplexé pour la quantification d'anticorps totaux et de médicaments conjugués à des anticorps
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
EP3458101B1 (fr) 2016-05-20 2020-12-30 H. Hoffnabb-La Roche Ag Conjugués anticorps-protac et procédés d'utilisation
WO2017205741A1 (fr) 2016-05-27 2017-11-30 Genentech, Inc. Procédé bioanalytique pour la caractérisation de conjugués anticorps-médicament spécifiques d'un site
CN109476648B (zh) 2016-06-06 2022-09-13 豪夫迈·罗氏有限公司 司维司群抗体-药物缀合物和使用方法
EP3496763A1 (fr) 2016-08-11 2019-06-19 Genentech, Inc. Promédicaments de pyrrolobenzodiazépine et conjugués d'anticorps de ceux-ci
EP3522933B1 (fr) 2016-10-05 2021-12-15 F. Hoffmann-La Roche AG Procédés de préparation de conjugués anticorps-médicament
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
SI3544636T1 (sl) 2017-02-08 2021-08-31 Adc Therapeutics Sa Konjugati pirolobenzodiazepin-protitelo
ES2926144T3 (es) 2017-04-18 2022-10-24 Medimmune Ltd Conjugados de pirrolobenzodiazepina
JP7408396B2 (ja) 2017-04-20 2024-01-05 アーデーセー セラピューティクス ソシエテ アノニム 併用療法
AU2018285562B2 (en) 2017-06-14 2024-01-18 Adc Therapeutics Sa Dosage regimes for the administration of an anti-CD19 ADC
JP7220203B2 (ja) 2017-08-18 2023-02-09 メドイミューン・リミテッド ピロロベンゾジアゼピン複合体
TW201920192A (zh) 2017-09-20 2019-06-01 韓商Ｐｈ製藥公司 泰蘭他汀（ｔｈａｉｌａｎｓｔａｔｉｎ）類似物
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
CN117925531A (zh) 2018-08-01 2024-04-26 南克维斯特公司 用于免疫疗法的基因修饰的包含归巢受体或细胞因子和嵌合抗原受体的四顺反子系统
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
JP2022505450A (ja) 2018-10-24 2022-01-14 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト コンジュゲート化された化学的分解誘導物質および使用方法
WO2020123275A1 (fr) 2018-12-10 2020-06-18 Genentech, Inc. Peptides de photoréticulation pour conjugaison spécifique de site à des protéines contenant fc
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
US11230699B2 (en) 2020-01-28 2022-01-25 Immunitybio, Inc. Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
CN114848822A (zh) * 2022-06-01 2022-08-05 合肥工业大学 Gpr31抑制剂在制备预防和治疗血管钙化药物中的应用
WO2024044659A1 (fr) * 2022-08-24 2024-02-29 Tectonic Therapeutic, Inc. Compositions de récepteur couplé à une protéine g constitutivement active et leurs procédés d'utilisation
WO2024138128A2 (fr) 2022-12-23 2024-06-27 Genentech, Inc. Conjugués d'agent de dégradation de céréblon et leurs utilisations

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2076386C (fr) 1990-02-26 2003-04-22 David S. Hogness Identification et expression d'une sequence d'adn d'insecte ayant les caracteristiques des recepteurs steroides d'insecte
CA2120518C (fr) 1991-10-01 1998-10-13 Monika Konig Methode d'identification de ligands et d'antagonistes de ligands
ATE365209T1 (de) * 1992-05-14 2007-07-15 Baylor College Medicine Mutierte steroidhormonrezeptoren, methoden für ihre benutzung und molekularer schalter für gentherapie
EP1063292A3 (fr) 1992-09-25 2001-04-25 Synaptic Pharmaceutical Corporation Adn codant des recepteurs adrenergiques alpha 1 humains et leurs utilisations
EP0612845A3 (en) 1993-02-26 1994-09-21 American Cyanamid Co Purified opioid receptor.
AU1173995A (en) 1993-11-10 1995-05-29 Arch Development Corporation Ubiquitous nuclear receptor: compositions and methods
JPH09504111A (ja) * 1993-12-30 1997-04-22 ザ ソールク インスチチュート フォア バイオロジカル スタディズ Ｇａｌ４−受容体構築体の新規な使用
US5573944A (en) 1994-07-22 1996-11-12 President And Fellows Of Harvard College Yeast cell expressing heterologous receptor kinase
WO1996005302A1 (fr) 1994-08-11 1996-02-22 Takeda Chemical Industries, Ltd. Proteine receptrice couplee a une proteine g, sa production et son utilisation
CA2135253A1 (fr) 1994-11-07 1996-05-08 Michael Dennis Depistage de composes grace a une fenetre d'activite independante du message chimique
JPH11506341A (ja) * 1995-06-06 1999-06-08 ヒューマン ジノーム サイエンシーズ，インコーポレイテッド Ｇタンパク質レセプターｈｔｎａｄ２９
CA2232733A1 (fr) 1995-09-20 1997-03-27 Orikkalapat Prem Das Recepteur de levure et proteine de fusion de proteine g
FR2742033B1 (fr) * 1995-12-08 1998-01-16 Achart Jacques Appareil pour l'ouverture de coquillages de mollusques bivalves
WO1997021731A1 (fr) 1995-12-11 1997-06-19 New England Medical Center Hospitals, Inc. Dosage et utilisations de ligands de recepteurs d'hormones peptidiques
US5750353A (en) 1995-12-11 1998-05-12 New England Medical Center Hospitals, Inc. Assay for non-peptide agonists to peptide hormone receptors
US5932779A (en) * 1996-06-10 1999-08-03 Millennium Pharmaceuticals, Inc. Screening methods for compounds useful in the regulation of body weight
US6399326B1 (en) 1996-07-02 2002-06-04 President And Fellows Of Harvard College Nucleic acids encoding neural/pancreatic receptor tyrosine phosphatase
JP2001501097A (ja) * 1996-09-24 2001-01-30 ケイダス ファーマスーティカル コーポレイション レセプターエフェクターを同定する方法及び組成物
JP2001508292A (ja) 1996-12-27 2001-06-26 メルク エンド カンパニー インコーポレーテッド ガラニンレセプターｇａｌｒ２及び該レセプターをコードするヌクレオチド
US6403305B1 (en) 1997-02-06 2002-06-11 Cornell Research Foundation, Inc. Methods of identifying peptide agonists or negative antagonists of a G protein coupled receptor
US6255089B1 (en) 1997-02-27 2001-07-03 Albany Medical College Constitutively activated serotonin receptors
ES2147167T1 (es) 1997-04-14 2000-09-01 Dominic P Behan Procedimiento de identificacion de moduladores de receptores de membrana de superficie celular util para el tratamiento de enfermedades.
US6555339B1 (en) * 1997-04-14 2003-04-29 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human protein-coupled receptors
US5891720A (en) 1997-04-17 1999-04-06 Millennium Pharmaceuticals, Inc. Isolated DNA encoding a novel human G-protein coupled receptor
EP0878542A3 (fr) 1997-04-22 2000-04-19 Smithkline Beecham Corporation Clone HMTMF81 de cADN codant pour un nouveau récepteur 7-transmembranaire humain
EP1007563A4 (fr) 1997-06-12 2003-04-16 Smithkline Beecham Corp Recepteur hm74a
US5955308A (en) 1997-06-18 1999-09-21 Smithkline Beecham Corporation cDNA clone HEAOD54 that encodes a human 7-transmembrane receptor
US6222029B1 (en) 1997-08-01 2001-04-24 Genset 5′ ESTs for secreted proteins expressed in brain
DE69837811D1 (de) 1997-11-11 2007-07-05 Ono Pharmaceutical Co Menschlicher lysophosphatidsäure rezeptor und dessen verwendung
SE9704836D0 (sv) 1997-12-22 1997-12-22 Astra Pharma Inc Novel receptor
ATE440865T1 (de) 1998-03-26 2009-09-15 Univ Leland Stanford Junior Neue g-protein-gekoppelte rezeptoren aus säugetieren mit extrazellulären leucin-reicher region
AU764766B2 (en) 1998-04-14 2003-08-28 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof
EP1095275B1 (fr) * 1998-07-31 2009-05-27 Arena Pharmaceuticals, Inc. Recepteurs orphelins endogenes a activation constitutive couples a la proteine g
AU5449099A (en) 1998-09-03 2000-03-27 Asahi Kasei Kabushiki Kaisha Novel receptor protein and method for diagnosing inflammatory diseases by using the same
WO2000022131A2 (fr) 1998-10-13 2000-04-20 Arena Pharmaceuticals, Inc. Recepteurs non-endogenes de la proteine g humaine ayant une activite constitutive
US20030229216A1 (en) * 1998-10-13 2003-12-11 Ruoping Chen Constitutively activated human G protein coupled receptors
CA2371821A1 (fr) 1999-02-19 2000-08-24 Takeda Chemical Industries, Ltd. Nouvelle proteine de recepteur couplee a la proteine g et adn
EP1200474A1 (fr) 1999-07-15 2002-05-02 Solvay Pharmaceuticals B.V. Recepteur humain couple a une proteine g
EP1196572A1 (fr) 1999-07-27 2002-04-17 Smithkline Beecham Plc Axor21, recepteur couple g-proteine
JP2003510027A (ja) 1999-08-17 2003-03-18 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング Ｐｇｐｃｒ−３ポリペプチドおよびそのｄｎａ配列
WO2001014577A1 (fr) 1999-08-24 2001-03-01 Smithkline Beecham Corporation Clonage moleculaire d'une galanine comme recepteur 7tm (axor40)
WO2001016159A1 (fr) 1999-08-27 2001-03-08 Smithkline Beecham Corporation Gpcr, ant
GB9923889D0 (en) 1999-10-08 1999-12-08 Pfizer Ltd Novel polypeptide
GB9924951D0 (en) 1999-10-21 1999-12-22 Pfizer Ltd Novel polypeptide
AU1575601A (en) 1999-10-27 2001-05-08 Pharmacia & Upjohn Company G protein-coupled receptors expressed in brain
IL149569A0 (en) 1999-11-17 2002-11-10 Arena Pharm Inc Endogenous and non-endogenous versions of human g protein-coupled receptors

Also Published As

Publication number Publication date
ES2163384T1 (es) 2002-02-01
WO2000022129A9 (fr) 2000-09-14
WO2000021987A3 (fr) 2000-07-13
EP1121431B9 (fr) 2007-10-24
CN1329511C (zh) 2007-08-01
DE69929993D1 (de) 2006-04-27
AU2011200511A1 (en) 2011-03-03
JP2003531565A (ja) 2003-10-28
WO2000021987A2 (fr) 2000-04-20
DE69929993T4 (de) 2008-08-28
IL141965A (en) 2008-08-07
AU769987B2 (en) 2004-02-12
ES2163384T3 (es) 2006-12-01
WO2000022129A1 (fr) 2000-04-20
ATE318311T1 (de) 2006-03-15
DE1121431T1 (de) 2002-05-23
KR20010085911A (ko) 2001-09-07
AU6430799A (en) 2000-05-01
NZ510331A (en) 2004-07-30
AU2004203102B2 (en) 2007-10-18
JP2002527727A (ja) 2002-08-27
DK1121431T5 (da) 2008-03-03
WO2000021987A9 (fr) 2000-08-24
IL141965A0 (en) 2002-03-10
AU2004203102A1 (en) 2004-07-29
CN1398298A (zh) 2003-02-19
US7410777B2 (en) 2008-08-12
DE69929993T2 (de) 2006-10-26
EP1121431B1 (fr) 2006-02-22
CA2342314A1 (fr) 2000-04-20
KR100598752B1 (ko) 2006-07-11
JP4672866B2 (ja) 2011-04-20
US20030105292A1 (en) 2003-06-05
JP4685241B2 (ja) 2011-05-18
EP1121431A1 (fr) 2001-08-08
AU2011200016A1 (en) 2011-01-27
US6555339B1 (en) 2003-04-29
AU2008200231A1 (en) 2008-02-07
DK1121431T3 (da) 2006-06-26

Similar Documents

Publication Publication Date Title
HK1038040A1 (en) Non-endogenous, constitutively activated human g protein-coupled receptors
ES2243095T3 (es) Receptores acoplados a proteina g humanos huerfanos.
Jüppner et al. The extracellular amino-terminal region of the parathyroid hormone (PTH)/PTH-related peptide receptor determines the binding affinity for carboxyl-terminal fragments of PTH-(1-34)
Krapivinsky et al. The G-protein-gated atrial K+ channel IKACh is a heteromultimer of two inwardly rectifying K+-channel proteins
Ulrich et al. Molecular cloning and functional expression of the human gallbladder cholecystokinin A receptor
US5883075A (en) Cyclic endothelin antagonists
Bullock et al. Structural determinants required for the bioactivities of prokineticins and identification of prokineticin receptor antagonists
EP0849361B1 (fr) Nouveaux ligands du recepteur de neuropeptides HFGAN72
Hoffmann et al. Residues within transmembrane helices 2 and 5 of the human gonadotropin-releasing hormone receptor contribute to agonist and antagonist binding
AU1769601A (en) Endogenous and non-endogenous versions of human G protein-coupled receptors
PT1012274E (pt) Receptor 4 contendo um domínio de morte (dm4; receptor de morte 4), membro da super-família do ftn e ligação a liart (ap02)
WO1998056820A1 (fr) Recepteur hm74a
Zhang et al. Structural analysis of angiotensin IV receptor (AT4) from selected bovine tissues
Unson et al. The role of histidine-1 in glucagon action
Delporte et al. Discovery of a potent atrial natriuretic peptide antagonist for ANPA receptors in the human neuroblastoma NB-OK-1 cell line
ES2201061T3 (es) Genes de receptores opioides delta.
Durek et al. Melanocortin 1 receptor agonists based on a bivalent, bicyclic peptide framework
Maiti et al. GnRH-II analogs for selective activation and inhibition of non-mammalian and type-II mammalian GnRH receptors
Mochizuki et al. Cloning and expression of the human 5-HT1B-type receptor gene
CA2330251A1 (fr) Clonage et identification du recepteur de la motiline
DK0692026T3 (da) En human T-cellereceptor fra den G-proteinkoblede receptorfamilie
Koshimizu et al. Truncation of the receptor carboxyl terminus impairs membrane signaling but not ligand binding of human ETB endothelin receptor
Suva et al. Design, synthesis and utility of novel benzophenone-containing calcitonin analogs for photoaffinity labeling the calcitonin receptor
Langer et al. Lysine 195 and aspartate 196 in the first extracellular loop of the VPAC1 receptor are essential for high affinity binding of agonists but not of antagonists
Chhajlani Characterization of a putative α-MSH antagonist 153N-6 at melanocortin receptor subtypes by radioligand binding

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20121012